Procter & Gamble Health Q1 FY27 profit up 45%

Key takeaway from Q1 FY27

Procter & Gamble Health Ltd. reported a sharp year-on-year jump in standalone net profit for Q1 FY27, but the headline growth was significantly influenced by an exceptional item. The company posted net profit of ₹96.15 crore for the quarter ended June 30, 2026, compared with ₹66.18 crore in the same quarter last year, marking a 45% increase. Revenue from operations rose to ₹363.71 crore, up 7.37% from ₹338.74 crore a year ago. The quarter included a one-time gain from the sale of an office premises property in Worli, which lifted reported profitability. Investors tracking quarterly earnings will likely separate the impact of this non-recurring gain from core operating performance.

Profit jumps, but exceptional gain plays a major role

The company’s Q1 FY27 results included an exceptional gain of ₹31.80 crore linked to the sale of its office premises in Worli. The property was sold for ₹33.34 crore against a carrying amount of ₹1.54 crore, resulting in the gain that was classified as an exceptional item under Ind AS. Alongside the reported profit surge, the company also disclosed net profit before exceptional items of ₹64.35 crore in Q1 FY27, slightly lower than ₹66.18 crore in Q1 FY26. This split is important because it shows that the rise in reported profit was not driven primarily by a step-up in underlying earnings during the quarter.

Revenue growth remains steady

Operationally, Procter & Gamble Health posted mid-single digit revenue growth. Revenue from operations increased from ₹338.74 crore in Q1 FY26 to ₹363.71 crore in Q1 FY27, a rise of 7.4% as presented in the company’s financial filing summary. Total income also moved higher to ₹367.59 crore, compared with ₹342.77 crore a year earlier. The numbers indicate that the business delivered top-line expansion even as the quarter’s profit optics were influenced by the asset sale.

Expenses rise year-on-year

Total expenses increased to ₹270.27 crore in Q1 FY27 from ₹253.96 crore in Q1 FY26. The company did not provide a detailed breakdown in the shared extract, but the headline expense growth stands out against the 7.4% rise in revenue from operations. With expenses rising, the operating picture becomes more relevant when looking at profit before exceptional items.

EBITDA and underlying profitability signals

In the quarter’s summary table, EBITDA was reported at ₹99.60 crore in Q1 FY27 versus ₹90.30 crore in Q1 FY26, reflecting a 10.3% increase. At the same time, net profit before exceptional items was ₹64.35 crore in Q1 FY27 versus ₹66.18 crore in Q1 FY26, a decline of 2.8%. This combination suggests operating performance improved on certain measures, but the bottom-line growth seen in reported profit was heavily aided by the exceptional gain.

Property sale details: Worli office premises

The sale of the Worli office premises was the most material one-off event in the quarter. The company recorded a sale value of ₹33.34 crore and a carrying amount of ₹1.54 crore, translating into an exceptional gain of ₹31.80 crore. Because such gains do not typically recur, market participants often adjust for them when assessing sustainable earnings and valuation.

EPS improves after exceptional items

Basic and diluted earnings per share (after exceptional items) stood at ₹57.92 for the quarter ended June 30, 2026. This compares with ₹39.87 in the same quarter last year. The movement in EPS mirrors the reported jump in net profit that includes the exceptional gain.

Board approval and audit review

The unaudited financial results for Q1 FY27 were reviewed by the Audit Committee and approved by the Board of Directors on August 6, 2026. The company stated that the financial results are in accordance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Haribhakti & Co. LLP, the statutory auditors, conducted a limited review and issued an unmodified conclusion, noting that nothing came to their attention indicating a material misstatement. The review was carried out in accordance with Standard on Review Engagements (SRE) 2410.

Quick investor datapoints disclosed alongside results

Alongside the results, the document carried several market and calendar datapoints. These included a reported market capitalisation of ₹10,963.06 crore and a current market price (CMP) of ₹6,604.5. The results date was listed as August 06, 2026. The same set of details also mentioned previous quarter revenue of ₹370.45 crore and previous quarter PAT of ₹94.60 crore.

P&G Health vs P&G Hygiene: contrast in quarterly trends

The broader Procter & Gamble listed ecosystem in India also saw a contrasting print from Procter & Gamble Hygiene and Health Care Ltd for the June quarter. P&G Hygiene reported profit after tax of ₹126 crore in Q1 FY27, down 34.25% from ₹192.06 crore a year ago, and EBITDA of ₹170 crore versus ₹266 crore in Q1 FY26. It reported EBITDA margin of 19.08% compared with 28.41% a year earlier. Revenue from operations for P&G Hygiene was stated at ₹891.46 crore for Q1 FY27, with the report also describing a 4.86% decline year-on-year.

Summary table: key Q1 FY27 numbers (P&G Health)

Exceptional item table: Worli property transaction (P&G Health)

Dividend-related disclosures in the same information set

The disclosures also referenced shareholder payouts for FY26. The board recommended a final dividend of ₹45 per share, subject to shareholder approval at the 59th AGM, and payable on or before September 25, 2026. It also stated that the company declared a total dividend of ₹205 per share for FY26, comprising an interim and special dividend of ₹160 per share declared in February 2026 and the final recommended dividend of ₹45 per share.

Conclusion

Procter & Gamble Health’s Q1 FY27 results combined steady revenue growth with a large one-time exceptional gain that lifted reported profit and EPS. The board-approved unaudited results and the auditor’s limited review provide the regulatory context for the filing, while the property sale explains much of the reported profit jump. Investors will likely track subsequent quarters to gauge how profit trends look without exceptional items, alongside any further updates from the company following the August 6, 2026 board process and the dividend timeline linked to the AGM.